Skip to main content
. 2011 Oct 5;2011(10):CD006423. doi: 10.1002/14651858.CD006423.pub2

Comparison 3. Exenatide 2 mg once weekly versus DPP‐4 inhibitors.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 HbA1c (%) 1   Mean Difference (IV, Random, 95% CI) Subtotals only
2 HbA1c < 7% 1   Risk Ratio (M‐H, Random, 95% CI) Subtotals only
3 Hypoglycaemia (minor) 1   Risk Ratio (M‐H, Random, 95% CI) Subtotals only
4 Weight change (kg) 1   Mean Difference (IV, Random, 95% CI) Subtotals only
5 Quality of life     Other data No numeric data
6 Adverse events     Other data No numeric data
7 Blood pressure (mm Hg)     Other data No numeric data
8 Fasting plasma glucose (mmol/L) 1   Mean Difference (IV, Random, 95% CI) Subtotals only
9 Post‐prandial glucose / glucose profiles     Other data No numeric data
10 Lipid profiles     Other data No numeric data